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Abstract Platelet activation is increasingly postulated as a
possible component of the pathogenesis of multiple sclerosis
(MS), especially due to the increased risk of cardiovascular
events in MS. Arachidonic acid cascade metabolized by
cyclooxygenase (COX) is a key pathway of platelet activa-
tion. The aim of our study was to investigate the COX-de-
pendent arachidonic acid metabolic pathway in blood
platelets from secondary progressive multiple sclerosis (SP
MS) patients. The blood samples were obtained from 50
patients (man n = 22; female n = 28), suffering from SP
MS, diagnosed according to the revised McDonald criteria.
Platelet aggregation was measured in platelet-rich plasma
after arachidonic acid stimulation. The level of COX activity
and thromboxane B2 concentration were determined by
ELISA method. Lipid peroxidation was assessed by mea-
suring the level of malondialdehyde. The results were
compared with a control group of healthy volunteers. We
found that blood platelets obtained from SP MS patients were
more sensitive to arachidonic acid and their response mea-
sured as platelet aggregation was stronger (about 14 %)
relative to control. We also observed a significantly
increased activity of COX (about 40 %) and synthesis of
thromboxane B2 (about 113 %). The generation of malon-
dialdehyde as a marker of lipid peroxidation was about 10 %
higher in SP MS than in control. Cyclooxygenase-dependent
arachidonic acid metabolism is significantly increased in
blood platelets of patients with SP MS. Future clinical
studies are required to recommend the use of low-dose
aspirin, and possibly other COX inhibitors in the prevention
of cardiovascular risk in MS.
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Introduction
Multiple sclerosis (MS) is a chronic neuroinflammatory
and immune-mediated disease associated with the forma-
tion of central nervous system (CNS) inflammatory plaques
as well as lesions exhibiting extensive demyelination,
along with loss of oligodendrocytes, neurons, and axons
[1]. MS is considered as a heterogeneous neurological
disease with various pathophysiological mechanisms and
multiple clinical course, but closely related to the damage
of intracerebral blood vessels, mainly as a result of
increased permeability of blood–brain barrier (BBB) as
well vessel occlusion [2]. There exists four subtypes of
MS: relapsing-remitting (RR), secondary progressive (SP),
primary progressive (PP), and progressive-relapsing (PR).
The most prevalent form of MS is RR MS, in which the
disease fluctuates between periods of inflammation and
demyelination, and remission. Ultimately, after several
years of disease duration, RR MS in approximately 70 %
of cases, converts into a SP MS in which patients suffer
irreversible disability progression. The progressive phase
of MS is believed to be secondary to neurodegenerative
changes triggered by inflammation. In progressive MS, as
in relapsing-remitting MS, active tissue injury is associated
& Agnieszka Morel
a_g_a@o2.pl
1 Faculty of Biology and Environmental Protection,
Department of General Biochemistry, University of Lodz,
Pomorska 141/143, 90-236 Lodz, Poland
2 Department of Physical Medicine, Medical University of
Lodz, Pl. Hallera 1, Lodz, Poland
3 Neurorehabilitation Ward, III General Hospital in Lodz,
Milionowa 14, Lodz, Poland
123
Mol Cell Biochem (2016) 420:85–94
DOI 10.1007/s11010-016-2770-6
with inflammation, but the inflammatory response in SP
MS occurs at least partly behind the blood–brain barrier
[3]. PP MS is characterized by worsening neurologic
function from the onset of symptoms, without relapses and
remissions. PR MS is one of the rarest subtype of MS
occurring in about 5 % of people with MS. In this subtype
of MS a steadily worsening of the disease from the
beginning and acute relapses are observed. The remissions
do not occur in patients with PR MS [4].
Epidemiological studies confirm an increased risk of
cardiovascular disease in MS, especially ischemic stroke
and myocardial infarction that is acute events directly
associated with abnormal platelet functions and their pro-
thrombotic activity [5, 6]. It is thought that blood platelets
play a crucial role in neurodegenerative processes, in which
an excessive activation of platelets are observed [7]. A
various bioactive compounds stored in platelet a-granules
and released upon their activation may affect the perme-
ability of BBB, and be crucial for the infiltration of
T-lymphocytes, responsible for the dissemination of new
inflammatory lesions in the CNS [8]. Our previous findings
suggest that increased platelet activation may be an
important cause of hemostatic disorders occurring in the
progressive stage of MS (SP MS). Platelets are most likely
important determinants in the pathogenesis of MS and
actively participate in oxidative stress existing in SP MS
[9]. Inhibition of platelet activation can provide measurable
benefits in suppressing the disease process in MS.
Upon platelet activation the signal transduction leads to
mobilization of calcium and increases its intracellular
concentration, resulting in phospholipases activation.
These enzymes hydrolyze phospholipids of cell membrane,
releasing e.g., the arachidonic acid (AA), which is a pre-
cursor of essential bioactive eicosanoids. AA is enzymat-
ically transformed by the cyclooxygenase (COX) to
intermediate products: prostaglandins and thromboxane A2
(TXA2), and then calcium is removed from intracellular
storage sites [10, 11]. TXA2 is a potent blood platelet
activator acting as proaggregatory and vasoconstrictor
mediator, which plays a pivotal role in the growth and
stabilization of a coronary thrombus [11]. This compound
is formed in response to the local stimuli and it exerts its
activating effect within a short distance of its biosynthesis.
COX activation is associated with prothrombotic platelet
activity and the production of proinflammatory eicosa-
noids. AA cascade metabolized by COX is a key pathway
of platelet activation. The addition of AA to platelet-rich
plasma in vitro, results in a burst of oxygen consumption,
TXA2 formation, and platelet aggregation [12]. The major
clinical indication for antiplatelet pharmacotherapy is the
prevention of arterial thrombosis. Clinically used agents
are based on interrupting specific sites in the sequence of
platelet activation. The results of clinical studies have
shown that intake of the antiplatelet agents as aspirin or
different aspirin-like COX inhibitors, at low doses reduces
the incidence of cardiovascular events [13]. Low-dose
aspirin supplementation reduced the risk of serious car-
diovascular events by 12 % and nonfatal myocardial
infarction by 18 % [14].
COX is an enzyme present in many types of cells. COX-
1 is constitutive cyclooxygenase involved both in the
maintenance of homeostasis in normal conditions and in
the early stages of an inflammatory reaction. The inducible
cyclooxygenase (COX-2) is involved in the later stages of
an inflammatory reaction when it starts the development of
the immune response. COX-1 is constitutively expressed in
blood platelets, as well as in neurons, astrocytes, and
microglial cells [15]. This enzyme plays a key role in the
conversion of AA to essential cell-signaling eicosanoids
which is accompanied by the production of reactive oxygen
species (ROS) [16]. It is believed that oxidative stress
might be responsible for brain inflammatory disorders
causing deleterious effects during CNS pathogenesis. What
is more, oxidative stress can activate several intracellular
signaling cascades that can have deleterious effects on the
cellular homeostasis [17].
Dysfunction of the mitochondrial system is thought to
play a major role in the mechanism of progression of
various neurodegenerative disorders, including demyeli-
nating disorders in MS. Although the weight of evidence
demonstrates that, while the development of pathology in
the early stages of MS is largely driven by inflammation,
mitochondrial dysfunction appears to have a critical role in
the progression of this disease [18]. Mitochondrial abnor-
malities in MS is presented by altered structure and dis-
tribution coupled with a wide array of molecular and
biochemical abnormalities [19–21]. In the studies con-
ducted by Mao et al. on the role of mitochondrial abnor-
malities in patients with MS and EAE mouse models, the
authors revealed that mitochondrial DNA defects, abnor-
mal mitochondrial gene expression, defective mitochon-
drial enzyme activities, deficient mitochondrial DNA repair
activity, and mitochondrial dysfunction are involved in the
development and progression of MS. They also explain that
mitochondrial abnormalities and mitochondrial energy
failure can impact other cellular pathways, including
increased demyelination and inflammation in neurons and
tissues that are affected by MS [22]. Deficient mitochon-
drial metabolism leads to the increased production
of ROS that can wreak havoc in the cell and which is
detrimental to neurons and glia [22, 23]. Therefore, mito-
chondria dysfunction is closely related to the mechanism
of neuroinflammation. In turn, neuroinflammation is
increasingly recognized to produce mitochondrial failure,
which then contributes to further neuronal injury and
degeneration [23].
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The main aim of our studies was to determine the patho-
physiological mechanisms of blood platelet activation rela-
ted to COX-1 activation in SP MS patients. We quantified
platelet activation by measuring the level of COX-1 activity
and TXB2 formation in patients diagnosed with SP MS using
ELISA methods. TXA2 as a main product of AA metabolism
itself is not stable enough for monitoring purpose. TXA2 is
rapidly metabolized into more stable metabolite—TXB2 that
can be detected in the serum. Moreover, we estimated the
reactivity of blood platelets assessing their aggregating
response to AA—as their physiological agonist. ROS gen-
eration and lipid peroxidation were determined by the level
of thiobarbituric acid reactive substances (TBARS) expres-
sed mainly as malondialdehyde (MDA) as the most common
marker of lipid peroxidation.
Materials and methods
Demographic and clinical characteristics
The blood samples were delivered from Neurological
Rehabilitation Division III General Hospital in Lodz,
Poland. Blood was collected from 50 patients (man n = 22;
female n = 28) suffering from SP MS. Patients were
observed for 1 year before and were diagnosed according to
the revised McDonald criteria. SP MS was ascertained as
defined by Lubin et al. [24]. Clinical parameters in patients
with SP MS: mean age -48.2 ± 15.2 years, mean disease
duration -14.3 ± 8.3 years, BMI -21.1 ± 9.7. The
patients were under Neurorehabilitation Ward control for
3 months and in that time they didn’t receive any
immunostimulators, immunomodulators, hormones, miner-
als, vitamins, or any other substitutions with antioxidative
effect. Treatment with immunomodulating therapies was not
used in this progressive stage of MS for almost 1 year. This
kind of inclusion criteria allow us to avoid interference of
effects of these drugs on oxidative stress parameters.
Control human blood samples were delivered from fifty
healthy volunteers, not taking any medications, who have
never been diagnosed with MS or other chronic disease and
without any neurological, hormonal illness, and any
chronic inflammatory. The control group and patients with
SP MS matched by the age and sex.
The protocol and all procedures were done according to the
Helsinki Declaration and were approved by Ethics Committee
of the Faculty of Biology and Environmental Protection of
University of Lodz, Poland No. 5/KBBN-UŁ/II/2013.
Isolation of platelet-rich plasma and blood platelets
The human blood samples (from control group and
patients) were collected into CPDA-1 (citrate phosphate
dextrose adenine-1), taken from a peripheral vein between
8 and 9 am in fasting status and stored using the same
protocol. The differential centrifugation of blood was used
for isolating platelet-rich plasma (PRP) for 10 min at
1500 rpm. To get blood platelets, PRP was centrifuged for
15 min at 2500 rpm. PRP was used to measure aggrega-
tion. The isolated and purified platelets were used to
determine the level of TBARS and activity of COX. The
final concentration of platelet suspension was approxi-
mately 4 9 108/ml. The number of platelets was counted
by the photometric method according to Walkowiak et al.
[25]. Platelets were suspended in the modified Tyrode’s
(Ca2?/Mg2?) free buffer (127 mM NaCl, 2.7 mM KCl,
0.5 mM NaH2PO4, 12 mM NaHCO3, 5 mM HEPES,
5.6 mM glucose, pH 7.4). Samples of blood platelets for
the determination of COX fluorescent activity were dis-
solved in lysis buffer 1:1 (7 M Urea, 2 M Thiourea, 4 %
CHAPS, 30 mM Tris).
Platelet aggregation
The platelet aggregation was measured turbidimetrically in
PRP using the optical Chrono-Log aggregometer (Chrono-
Log, Havertown, PA). After preincubation of PRP
(3 9 108 platelets/ml, at 37 C for 5 min) physiological
agonist was added—free AA (1 mM). The aggregation was
measured with stirring by the duration of 10 min. The
results are presented as a percentage of the aggregation.
The maximal aggregation (100 %) was defined as the light
transmission observed in PPP (platelet-poor plasma).
Determining the COX-1 fluorescent activity
In platelet lysates obtained from patients with SP MS and
healthy volunteers the level of COX-1 activity was deter-
mined by the fluorescence-based method, using COX
Fluorescent Activity Assay Kit (Cayman Chemicals). The
oxygenase activity of COX is responsible for the conver-
sion of arachidonic acid to a hydroperoxy-endoperoxide
(PGG2). In this assay, the reaction between PGG2 and
ADHP (10-acetyl-3,7-dihydroxyphenoxazine) produces the
highly fluorescent compound resorufin that can be analyzed
using an excitation wavelength of 530–540 nm and an
emission wavelength of 585–595 nm. The results are pre-
sented in nmol/min/ml.
Determining the level of TXB2 by competitive
ELISA assay
The human blood samples (from control group and
patients) were collected into serum tubes with coagulation
activator (without anticoagulant). To quantify the level of
TXB2 in serum obtained from SP MS patients and healthy
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control, the Thromboxane B2 Express ELISA Kit—Mon-
oclonal (Cayman Chemicals) was used. The total level of
TXB2 in all samples was expressed in pg/ml.
Thiobarbituric acid reactive substances estimation
Samples of blood platelet suspended in the modified Tyr-
ode’s buffer were mixed with an equal volume of 15 % (w/
v) cold trichloroacetic acid in 0.25 M HCl and with an
equal volume of 0.37 % (w/v) thiobarbituric acid in
0.25 M HCl. All samples were immersed in a boiling water
bath for 10 min. After cooling samples were centrifuged
and then the absorbance at 535 nm was measured. The
results were expressed as nmoles of MDA per ml of pla-
telet suspension, as we described previously [26].
Statistical analysis
The statistical analysis was performed using StatsDirect
statistical software V. 2.7.2. All values were expressed as a
mean ± SD. To analyze the normality of the distribution of
results, the Shapiro–Wilk test was used. The significance of
differences between the values were analyzed depending
on the normality by unpaired t-student (for data with nor-
mal distribution) or U-Mann–Whitney (for data with
abnormal distribution) tests. Spearman’s rank correlation
was used in correlation analysis between markers of pla-
telet activation (COX-1, TXB2) and clinical parameter of
physical disability—EDSS scores. A level of p\ 0.05 was
accepted as statistically significant.
Results
Measurement of platelet aggregation was performed on
each sample. To ensure full platelet activation a physio-
logical stimulus—AA (1 mM) was added. The amounts of
agonist was constant and sufficient to activate platelets in
whole samples. The activation of platelets in PRP upon AA
stimulation resulted in the statistically significant increase
in the platelet aggregation (p\ 0.0001) in SP MS patients
versus control group (Fig. 1a, b). The level of platelet
aggregation increased from 87 % for healthy control to
99 % for SP MS patients (growth of 14 % of control—
when the value of the control was taken as 100 %)
(Fig. 1a).
Moreover, our results clearly indicated the statistically
significant increase in basal platelet activation state in
patients with SP MS compared with healthy individuals.
The level of oxygenase activity of COX-1 measured in
platelets by ELISA method, was higher over 40 %
(p\ 0.0001) in SP MS patients than in control group
(Fig. 2). Similarly, we observed the statistically significant
increase in the production of thromboxane (p\ 0.0001).
The concentration of TXB2, determined by ELISA method,
in blood platelets derived from SP MS patients was more
than twofold higher than in controls (Fig. 3). Our results
also revealed that in blood platelets from patients with SP
MS the synthesis of AA metabolites, measured as the
amount of TBARS, and expressed as nmoles of MDA per
ml of platelet suspension, was increased by approximately
10 % (p\ 0.02) compared with healthy subjects (Fig. 4).
We also established the positive correlation between the
level of COX-1 activity (Fig. 5; Table 1), the level of
TXB2 (Fig. 6; Table 1), and EDSS score.
Discussion
Some studies suggest that patients with multiple sclerosis
have an increased risk for cardiovascular events, for
example, venous thromboembolism, ischemic strokes, and
myocardial infarction. These clinical observations suggest
that there is a possibility that aspirin (or other aspirin-like
drugs) could diminish this increased risk in this population
[27]. Aspirin (acetylsalicylic acid) is a well known and
popular COX inhibitor, and it is often used for the sec-
ondary prevention of cardiovascular events in patients at
elevated risk. This drug has the potential to limit some
components of inflammation (production of proinflamma-
tory cytokines and ROS by microglia) and may also posi-
tively impact other disease process in multiple sclerosis, for
example, it is likely to facilitate remyelination efforts by
promoting the proliferation and differentiation of oligo-
dendrocyte precursors [28].
In Modi et al. [29] research on the role of ASA in MS
patients, the authors clearly support the conclusion that
aspirin is capable of up-regulating ciliary neurotrophic
factor (CNTF) in mouse in vitro and human astrocytes
in vitro. Aspirin may ameliorate demyelination. Aspirin-
induced astroglial CNTF was also functionally active
because the supernatants of aspirin-treated wild type (WT),
but not CNTF-/-, astrocytes-supported oligodendroglial
growth as evidenced by increased expression of proteolipid
protein (PLP) and myelin oligodendrocyte glycoprotein
(MOG). Furthermore, aspirin-induced CNTF-protected
oligodendroglia from TNF-a-induced apoptosis and cell
death. The authors have demonstrated that aspirin, a widely
used analgesic, up-regulates CNTF via PKA-mediated
activation of cAMP response element-binding protein
(CREB) and that aspirin-treated astroglial supernatant
protects oligodendroglia from inflammatory insult via
CNTF. Although the in vitro situation of mouse astrocytes
and oligodendrocytes in culture and its treatment with
aspirin may not truly resemble the in vivo situation of these
cells in the brain of MS patients, these results highlight an
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undiscovered property of aspirin and indicate that this drug
may be used for therapeutic intervention in MS and other
demyelinating conditions as primary or adjunct therapy.
Acetylsalicylic acid has been shown to be effective in
reducing cardiovascular disease conditions associated with
thrombosis and an increased blood platelet activation. The
inhibitory action of aspirin on platelet function is due to
acetylation of the platelet cyclooxygenase at the function-
ally important amino acid Ser-529 of COX-1 and Ser-516
of COX-2. This prevents the access of arachidonic acid
(COX substrate) to the enzyme catalytic site at Tyr-385 and
results in an irreversible inhibition of platelet formation of
prothrombotic and proinflammatory mediators [30]. COX
is a membrane-bound glycoprotein which possesses two
distinct enzymatic activities: oxygenase and peroxidase.
The COX pathway is substrate limited and is strictly
dependent on the release of arachidonic acid from the
phospholipid membrane, because only free, unesterified
AA is an oxygenase substrate [31]. AA is a prominent fatty
acid in platelet phospholipids and phosphatidylcholine,
phosphatidylethanolamine, and phosphatidylinositol con-
tain even 80 % of arachidonate. Enzymes participate in AA
release are phospholipase A2 and phospholipase C. Free
arachidonic acid is the substrate for the synthesis of
Fig. 1 Blood platelet
aggregation induced by
arachidonic acid in platelet-rich
plasma. Data represent
mean ± SD, n = 50. Statistical
analysis was performed using
Mann–Whitney U-test
*p\ 0.0001 SP MS versus
control (a). Typical curve of
platelet aggregation in PRP after
stimulation of platelets with AA
(Chrono-Log aggregometer,
Havertown, PA) (b)
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biologically active eicosanoids (prostaglandins and
thromboxanes) [10]. The initial step in their synthesis is
oxygenation of AA at C-11 by COX. The oxygenase
activity catalyses the incorporation of two oxygen mole-
cules to one molecule of arachidonate, creating a pros-
taglandin PGG2. After oxidation, the enzyme is irreversibly
inactivated by self-destruction. While peroxidase catalysis
results in the reduction of 15-OOH group of PGG2 to
15-OH, and formation of PGH2, which is a substrate for
thromboxane synthesis [32]. TXA2 is a potent stimulus to
platelet aggregation, as well a major second mediator in the
platelet response to exogenous agonists. TXA2 is an
unstable molecule with a short half-life about 30 s., after
which it passes to the stable but inactive compound TXB2
[33]. Participation of blood platelets in both physiological
processes and pathological conditions is dependent on their
activation. The resting platelets do not contain free
arachidonate and therefore there is no pathway of platelet
AA metabolism. Since both the enzymes (phospholipases
C and A2) involved in hydrolysis of membrane phospho-
lipids, are calcium dependent, release of free AA is evi-





























Fig. 2 The level of oxygenase activity of COX-1 in platelet lysates
from SP MS patients and healthy controls. Data represent
mean ± SD, n = 50. Statistical analysis was performed using
unpaired t-test *p\ 0.0001 SP MS versus control
Fig. 3 The concentration of TXB2 in serum obtained from SP MS
patients and healthy controls. Data represent mean ± SD, n = 34.
Statistical analysis was performed using unpaired t-test *p\ 0.0001


































Fig. 4 The level of TBARS concentration measured in platelet
samples obtained from SP MS patients and healthy controls. Data
represent mean ± SD and are expressed as nmol of MDA/ml of
platelet suspension, n = 35. Statistical analysis was performed using
unpaired t-test *p\ 0.02 SP MS versus control





























Fig. 5 Regression plot of COX-1 activity in platelets obtained from
SP MS patients and EDSS score
Table 1 Correlation coefficient values obtained for level of COX-1
activity, level of TXB2, and EDSS score
COX-1 TXB2
EDSS
Spearman’s rank correlation (q) 0.6223 0.6155
Probability for correlation p = 0.00001 p = 0.0001
Correlation was analyzed using Spearman’s rank correlation method.
Table consists Spearman’s rank correlation coefficient (q) and prob-
ability for correlation (p)
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It is thought that platelet activation may be an epiphe-
nomenon consequent to the disease processes in MS,
probably secondary to endothelial injury, which causes the
exposure of platelets to a variety of stimuli. Some reports
emphasize the importance of platelet activation in MS [35].
Our previous studies also clearly demonstrated that blood
platelets are chronically activated in the circulation of SP
MS patients [36]. However, there are numerous studies
describing the physiology of platelets in the relapsing-
remitting phase of MS (RR MS)—the first stage of disease
and the most common disease course, but only very few
studies on the role of platelets in SP MS. Among the
existing studies, the differences in platelet activation
parameters between RR MS and SP MS exist. Higher level
of sP-selectin and other markers of platelet activation [37],
as well as an increase of PAF activity [38] were observed
in RR MS compared to secondary progressive MS. In
Sa´enz-Cuesta et al. studies, the authors observed the higher
level of the platelet-derived microparticles (MPs) in
patients with RR MS than in SP MS [39].
Based on the fact that each clinical phase of MS should
be considered as a distinct disease entity [40], we focused
our attention on the alterations of platelets in progressive
phase (SP MS) characterized by irreversible disability
progression [41]. In our previous studies the elevated
activation of platelets and an increased aggregation in
response to typical physiological agonists (ADP, collagen)
have been observed in SM patients [9, 36]. Activation of
COX pathway is recognized to participate in intraplatelet
events associated with aggregation. After platelet activa-
tion by thrombin, collagen or ADP, synthesis of TXA2 is
responsible for platelet aggregation. Synthesized eicosa-
noids are not stores, and therefore, the action of TXA2
indicates the activation of COX [42]. COX-dependent
metabolism of AA is a key pathway of platelet activation.
In the present study we focused on the assessment of
changes of COX- dependent arachidonic acid metabolism
in blood platelets from SP MS patients. Our results
demonstrate that oxygenase activity of COX in platelets
from SP MS patients is significantly elevated (about 40 %)
compared to platelets from healthy control (Fig. 2). Also
peroxidase activity of COX is significantly higher in SP
MS patients, which results in pronounced, more than
twofold increase in the concentration of TXB2 (Fig. 3). In
these studies, for the first time, we have shown the positive
correlations between the level of COX-1 activity (Fig. 5;
Table 1) and the level of TXB2 (Fig. 6; Table 1) in blood
platelets obtained from SP MS patients with the clinical
parameter EDSS score. It clearly indicates that the platelet
activation is associated with the physical disability of dis-
ease. Our earlier and current findings confirm the abnor-
malities in platelet hemostatic function and indicate the
elevated platelet activation. We postulate that it is probably
related to a direct action of thromboxane, which modifies
the response of platelets to exogenous agonists as well as
alone stimulates platelet activation. Platelet surface
receptor for TXA2 (TP) is a member of the seven-trans-
membrane G protein-coupled receptor superfamily. Bind-
ing of ligand to TP results in both autocrine and paracrine
action of TXA2 released from blood platelets. In TP sig-
naling pathway two G proteins are involved: Gq and G12/13.
Stimulation of Gq activates phospholipase C, resulting in
the accumulation of inositol 1,4,5-trisphosphate causing
intraplatelet calcium mobilization, and diacylglycerol for-
mation, which induces activation of protein kinase C. In
platelets, this signaling results in platelet shape change,
aggregation, and secretion. Stimulation of G12/13 activates
the Rho/Rho kinase pathway and subsequent myosin light
chain phosphorylation, which is responsible for TP-medi-
ated platelet shape change [33].
Our present studies were designed to demonstrate the
platelet aggregation induced by extracellular AA. The
exogenous arachidonic acid is able to cause platelet irre-
versible aggregation, because it may be rapidly incorporated
into membrane phospholipids, primarily phosphatidylcholine
and phosphatidylinositol, by arachidonoyl-coenzyme A syn-
thetase. This aggregation response induced by exogenous AA
depends on COX activity, and is inhibited by aspirin [43]. In
our experiments the platelet aggregation measured in PRP
derived from SP MS was higher by about 17 % than in
healthy control (Fig. 1). Our previous and current results
indicate that platelets from SP MS patients are much more
sensitive to physiological agonists and their responsiveness is
stronger than platelets from healthy subjects.
It is well known, that platelet arachidonate metabolism
generates a great amount of ROS. After platelet activation,
COX rapidly metabolizes free AA to PGH2 causing the
burst of oxygen consumption [44]. ROS generation induces




























Fig. 6 Regression plot of TXB2 level in platelets obtained from SP
MS patients and EDSS score
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lipid peroxidation that is responsible for changes in the
fluidity of membranes, their permeability, and exposition
of the receptors, and results in changes in signal trans-
duction [45]. Our studies confirm the elevated level (by
about 10 %) of lipid peroxidation in platelets obtained
from SP MS patients (Fig. 4).
ROS are implicated in the regulation of platelet function
and may be produced as second messengers, in the recep-
tor-mediated signaling pathways during platelet activation
[46]. Many pathogenic processes, including blood platelet
hyperactivity, may be initiated by injury action of ROS;
therefore, blood platelets link the processes of hemostasis,
thrombosis, and inflammation. The superoxide radicals
may interact with iron (accumulated in the brain in SP MS)
and form reactive hydroxyl radicals that attack polyunsat-
urated fatty acids, leading to lipid peroxidation and
demyelination [9]. In blood platelets, the main target of
ROS/RNS action are proteins [4, 47]. They can be modu-
lated in direct and indirect ways. Direct modifications
involve: nitration, carbonylation, and disulfide bond for-
mation [48, 49]. Exposure of platelet proteins to ROS/RNS
can alter every level of protein structure from primary to
quaternary, causing major physical changes in protein
structure [4, 47, 48]. The oxidative/nitrative damage of
platelet proteins leads to the peptide backbone cleavage,
cross-linking, and/or modifications of the side chain of
every amino acid [50]. The increased protein aggregates, in
turn overwhelms the degradation systems which results in a
self-perpetuating cycle and further oxidative stress. The
great number of protein injury is irreparable, and oxidative/
nitrative changes of protein structure have functional con-
sequences, such as an inhibition of enzymatic activities, a
misfolding, an increased ability of proteins for aggregation
and proteolysis, and an altered immunogenicity [51].
Individual proteins can display different susceptibilities to
oxidative attack, linked to the distribution of sulfhydryl
(SH) groups [52]. ONOO- is a highly reactive compound
that modify tyrosine residues resulting in protein nitration,
expressed as a 3-NT [53–55]. Tyrosine nitration inhibits
the activity of manganese superoxide dismutase and
phosphorylation process which leads to the redox imbal-
ance and disturbances in signaling pathways [56].
The main function of blood platelets is their hemostatic
contribution, but evidences show that processes of platelet
activation may be sometimes a critical link between
hemostasis and development of inflammation. Platelets are
activated in MS and have been implicated in contributing
to MS pathogenesis, such as by promoting inflammation
[26, 35]. Our results demonstrate, that the activation of
platelets from SP MS patients is significantly raised com-
pared to platelets from healthy subjects, and observed
differences are directly related to the COX activation. COX
may be inhibited by aspirin-like drugs, and inhibition is
limited to the oxygenase activity, while peroxidase action
is intact [57, 58]. Aspirin is the most well-tolerated and
effective antithrombotic agent. Aspirin is an approximately
150- to 200-fold more potent inhibitor of the constitutive
isoform of platelet enzyme responsible for TXA2 synthesis,
than the inducible isoform which is expressed by inflam-
matory mediators. This explains the different dosage
requirements of aspirin as an antithrombotic (COX-1) and
an antiinflammatory drug (COX-2), respectively [27].
Because, as we have shown in the work, increased
platelet activity and their high reactivity in the circulation
of SP MS patients is associated with elevated activity of
COX, preventive use of safe doses of aspirin could reduce
the number of cardiovascular events in these patients. The
role of new, more specific antiplatelet drugs may also hold
future promise in reducing dimension of platelet activation,
and production of ROS and proinflammatory mediators.
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